# Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/synthetic-cannabinoids-schedule-i-designation/ > **Published:** 2026-06-02T12:52:18-04:00 | **Last Modified / Clinically Audited:** 2026-09-29T00:30:33-04:00 > **Clinical Summary:** Explore the synthetic cannabinoids schedule I designation and DEA's regulatory actions on CUMYL-PEGACLONE under the Controlled Substances Act. --- ✦ New CED Clinical Relevance #70 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Policy Watch  |  Federal Register cannabis_policyfederal_lawDEA_schedulingcontrolled_substancesCUMYL-PEGACLONESchedule_Istate_regulation Clinical Summary The Drug Enforcement Administration has placed CUMYL-PEGACLONE, a synthetic cannabinoid, into Schedule I of the [Controlled Substances](https://cedclinic.com/dea-scheduling-cannabis-policy-march-15-2026/) Act due to its high abuse potential and lack of accepted medical use. This regulatory action reflects ongoing efforts to control designer cannabinoids that are chemically modified to evade existing drug laws while maintaining psychoactive effects similar to cannabis or more potent synthetic cannabinoids. Clinicians should be aware that Schedule I designation means the substance has no legal medical application and carries severe criminal penalties for possession or distribution, which may affect patient counseling regarding substance use risks. The placement of novel synthetic cannabinoids into Schedule I underscores the challenge of regulating rapidly evolving cannabis analogs that appear on the illicit market faster than formal scheduling can occur. Patients presenting with acute effects from these emerging synthetic cannabinoids may require supportive care similar to that provided for traditional cannabis or other cannabinoid toxidromes, though specific toxicity profiles for newer compounds remain poorly characterized. Clinicians should maintain awareness of Schedule I designations for designer cannabinoids to provide accurate risk counseling and recognize potential toxidromes in patients reporting use of unidentified cannabinoid products. Dr. Caplan’s Take “The DEA’s scheduling of novel synthetic cannabinoids like cumyl-pegaclone reflects a regulatory system that’s fundamentally reactive rather than proactive, and this gap between emerging compounds and scheduling decisions means my patients are often exposed to untested substances with unpredictable pharmacology before we have any clinical data on safety or efficacy. What we really need is a scheduling framework that allows legitimate [medical research](https://cedclinic.com/cb2-receptor-agonist-parkinsons/) to proceed in parallel with [public health](https://cedclinic.com/cannabis-mold-contamination-risks-recall-safety/) protections, rather than forcing everyone into this artificial choice between prohibition and the unknown.” Clinical Perspective The DEA’s scheduling of synthetic cannabinoid CUMYL-PEGACLONE into Schedule I reflects ongoing regulatory efforts to address the evolving landscape of novel psychoactive substances, which often evade existing drug laws through minor chemical modifications. Clinicians should recognize that synthetic cannabinoids, including newly scheduled compounds, continue to appear in community settings and may be misrepresented to patients as legal alternatives to cannabis, creating diagnostic and treatment challenges when patients present with acute psychiatric symptoms, tachycardia, or [cannabinoid hyperemesis](https://cedclinic.com/cannabis-hyperemesis-syndrome-virginia-er-cases-surge/) syndrome. The rapid pace of structural innovation in this class means that scheduling actions are inherently reactive rather than preventive, and regulatory status does not necessarily correlate with pharmacological potency or clinical harm. When obtaining substance use history, providers should specifically ask about use of “K2,” “Spice,” or “herbal incense” products, as patients may not associate these with cannabis or 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/ask-dr-caplan/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just+read+this+on+CEDclinic.com%3A+Schedules+of+Controlled+Substances%3A+Placement+of+CUMYL-PEGACLONE+in+Schedule+I+%40drcaplan&url=https%3A%2F%2Fwww.federalregister.gov%2Fdocuments%2F2026%2F05%2F13%2F2026-09566%2Fschedules-of-controlled-substances-placement-of-cumyl-pegaclone-in-schedule-i)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fwww.federalregister.gov%2Fdocuments%2F2026%2F05%2F13%2F2026-09566%2Fschedules-of-controlled-substances-placement-of-cumyl-pegaclone-in-schedule-i)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just+read+this%3A+Schedules+of+Controlled+Substances%3A+Placement+of+CUMYL-PEGACLONE+in+Schedule+I+--+via+%40drcaplan.bsky.social+https%3A%2F%2Fwww.federalregister.gov%2Fdocuments%2F2026%2F05%2F13%2F2026-09566%2Fschedules-of-controlled-substances-placement-of-cumyl-pegaclone-in-schedule-i)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/) Further Reading CED Clinic Blog[Why Cannabis Works](https://cedclinic.com/why-cannabis-works/) Evidence Watch[Cannabis and Heart Health](https://cedclinic.com/cannabis-cardiovascular-health-study/) CED Clinic Blog[Cannabis for Sleep](https://cedclinic.com/cannabis-for-sleep/) Related Articles - [Schedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule I](https://cedclinic.com/dea-synthetic-ketamine-analog-control-2-fdck-schedule-i/) - Schedules of [Controlled Substances](https://cedclinic.com/dea-scheduling-cannabis-policy-march-15-2026/): Placement of Diphenidine in Schedule I - [Some Cannabinoids May Ease Common Chronic Pain Conditions, Study Finds – Forbes](https://cedclinic.com/cannabinoid-efficacy-data-chronic-pain-conditions-study/) 📰 Source: [https://www.federalregister.gov/documents/2026/05/13/2026-09566/schedules-of-controlled-substances-placement-of-cumyl-pegaclone-in-schedule-i](https://www.federalregister.gov/documents/2026/05/13/2026-09566/schedules-of-controlled-substances-placement-of-cumyl-pegaclone-in-schedule-i) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [DEA Places Synthetic Cannabinoid CUMYL-PEGACLONE in Schedule I](https://cedclinic.com/cumyl-pegaclone-schedule-i-placement-dea-synthetic-cannabinoid/) Detailed analysis of the DEA’s decision to place CUMYL-PEGACLONE in Schedule I and its implications for [clinical practice](https://cedclinic.com/cannabis-reproductive-health-women-clinical-evidence/) and regulation. [Read More](https://cedclinic.com/cumyl-pegaclone-schedule-i-placement-dea-synthetic-cannabinoid/) [Schedules of Controlled Substances: Placement of Diphenidine in Schedule I](https://cedclinic.com/diphenidine-regulatory-scheduling-update-schedule-i/) Explore the scheduling of Diphenidine in Schedule I and the broader context of synthetic drug regulation. [Explore Article](https://cedclinic.com/diphenidine-regulatory-scheduling-update-schedule-i/) [Schedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule I](https://cedclinic.com/dea-synthetic-ketamine-analog-control-2-fdck-schedule-i/) An overview of the temporary scheduling of 2-Fluorodeschloroketamine and its regulatory significance. [Learn More](https://cedclinic.com/dea-synthetic-ketamine-analog-control-2-fdck-schedule-i/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).